A Comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in Pulmonary Neuroendocrine Tumors

Our purpose was to compare the performance of 68Ga-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid-d-Phe1,Tyr3-octreotate (DOTATATE), a novel selective somatostatin receptor 2 PET ligand, and 18F-FDG in the detection of pulmonary neuroendocrine tumors using PET/CT, with correlation of uptake and tumor grade on histology. Methods: The imaging findings of the first 18 consecutive patients (8 men and 10 women) with pulmonary neuroendocrine tumors (11 typical carcinoids, 2 atypical carcinoids, 1 large cell neuroendocrine tumor, 1 small cell neuroendocrine carcinoma, 1 non–small cell lung cancer with neuroendocrine differentiation, and 2 cases of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia) who underwent 68Ga-DOTATATE and 18F-FDG PET/CT were reviewed. In all cases, the diagnosis was established on histology. Results: Of 18 patients, 15 had primary tumors (median size, 2.7 cm; range, 0.5–8 cm) and 3 had recurrent tumors. All typical carcinoids showed high uptake of 68Ga-DOTATATE (maximum standardized uptake value [SUVmax] ≥ 8.2), but 4 of 11 showed negative or minimal 18F-FDG uptake (SUVmax = 1.7–2.9). All tumors of higher grade showed high uptake of 18F-FDG (SUVmax ≥ 11.7), but 3 of 5 showed only minimal accumulation of 68Ga-DOTATATE (SUVmax = 2.2–2.8). Neither case of diffuse idiopathic pulmonary neuroendocrine cell hyperplasia showed uptake of 68Ga-DOTATATE or 18F-FDG. Typical carcinoids showed significantly higher uptake of 68Ga-DOTATATE and significantly less uptake of 18F-FDG than did tumors of higher grade (P = 0.002 and 0.005). There was no instance of false-positive uptake of 68Ga-DOTATATE, but there were 3 sites of 18F-FDG uptake secondary to inflammation. 68Ga-DOTATATE was superior to 18F-FDG in discriminating endobronchial tumor from distal collapsed lung (P = 0.02). Conclusion: Typical bronchial carcinoids showed higher and more selective uptake of 68Ga-DOTATATE than of 18F-FDG. Atypical carcinoids and higher grades had less 68Ga-DOTATATE avidity but were 18F-FDG–avid.

[1]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  J. Tabernero,et al.  Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. , 2007, Endocrine-related cancer.

[3]  R. Baum,et al.  Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  A. Nicholson,et al.  Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: an under-recognised spectrum of disease , 2006, Thorax.

[5]  T. Meyer,et al.  Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. , 2009, Lung cancer.

[6]  G. Rossi,et al.  Bronchial typical carcinoid tumors. , 2006, Seminars in thoracic and cardiovascular surgery.

[7]  Y. Soini,et al.  Atypical bronchopulmonary carcinoids show a tendency toward increased apoptotic and proliferative activity , 2000, Cancer.

[8]  K Schnabel,et al.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. , 1999, International journal of radiation oncology, biology, physics.

[9]  R. Bale,et al.  68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007, Journal of Nuclear Medicine.

[10]  P C Goodman,et al.  Evaluation of primary pulmonary carcinoid tumors using FDG PET. , 1998, AJR. American journal of roentgenology.

[11]  F. Mottaghy,et al.  Use of integrated FDG PET/CT imaging in pulmonary carcinoid tumours , 2006, Journal of internal medicine.

[12]  J. Charboneau,et al.  Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. , 1990, Cancer research.

[13]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[14]  E. Krenning,et al.  Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  R. Rosell,et al.  PET/CT fusion scan in lung cancer: current recommendations and innovations. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  V. Lowe,et al.  The utility of fluorodeoxyglucose positron emission tomography in the evaluation of carcinoid tumors presenting as pulmonary nodules. , 2007, Chest.

[17]  J. Choi,et al.  Integrated PET/CT of pulmonary neuroendocrine tumors: diagnostic and prognostic implications. , 2007, AJR. American journal of roentgenology.

[18]  P. Gattuso,et al.  Well-differentiated neuroendocrine carcinomas: the spectrum of histologic subtypes and various clinical behaviors. , 2006, Seminars in thoracic and cardiovascular surgery.

[19]  W. Travis,et al.  The new World Health Organization classification of lung tumours , 2001, European Respiratory Journal.

[20]  Giovanni Paganelli,et al.  Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  M. Chung,et al.  Neuroendocrine tumors of the lung: clinical, pathologic, and imaging findings. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[22]  A. Groves,et al.  Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐DPhe1,Tyr3‐octreotate) and 18F‐FDG , 2008, Cancer.